We are live on ! Find out more

SiNtx Technologies

SINT

Market cap $13M

1.72 USD

+0.01

0.58%

At close Updated Nov 3, 4:00 PM EST

1 day

0.58%

5 days

0.58%

1 month

-21.1%

3 months

-2.82%

6 months

-28.93%

Year to date

-54.5%

1 year

-48.5%

5 years

-99.99%

10 years

-100%

About: SINTX Technologies Inc is a biomaterials company that develops, manufactures, and commercializes patented and proprietary silicon nitride ceramic biomaterials, composites, devices, and related ceramics technologies for other medical and specialized industrial applications. SINTX has 20 years' experience innovating silicon nitride technologies and operates under a quality management system certified to ISO 13485:2016 and AS9100D, with a product portfolio that includes insulators for Tier 1 aerospace suppliers, the FDA-cleared SiNAPTIC Foot & Ankle Osteotomy Wedge System for reconstructive surgery, OEM manufacturing of FDA-cleared spinal implants, and its SiNERGY technology platform being developed for biocomposite and 3D printing applications.

Employees: 32

Healthcare Medical Devices

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 22.2%

Neutral 77.8%

Negative 0%

SINTX Technologies Announces Third Quarter 2026 Earnings Release Date and Webcast

SALT LAKE CITY, Utah, Oct. 22, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a leader in advanced silicon nitride biomaterials and ceramics for medical and industrial applications, today announced that it will release its third quarter 2026 financial results on Thursday, November 5, 2026, after the market close. The Company will also host a conference call and webcast that day at 4:30 p.m.

SINTX Technologies Announces Third Quarter 2026 Earnings Release Date and Webcast

Zacks Investment Research

What Makes SINTX TECHNOLOGIES (SINT) a New Buy Stock

SINTX TECHNOLOGIES (SINT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes SINTX TECHNOLOGIES (SINT) a New Buy Stock

SINTX Announces Preliminary $2.2 Million in Q3 Revenue, Exceeding High-End Guidance

Third-quarter revenue grows roughly 380% from Q2, driven by stronger-than-expected industrial sales to Fortune 500 customers; Company reiterates Q4 revenue guidance Revenue milestone also enables Company to call Class B warrants SALT LAKE CITY, Utah, Oct. 01, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a leader in advanced silicon nitride biomaterials and ceramics for medical and industrial applications, today announced preliminary, unaudited revenue of $2.2 million* for the third quarter ended September 30, 2026. The result exceeds the high end of the Company's previously announced guidance of $0.9 million to $1.1 million, reflecting stronger-than-expected industrial ceramics sales, and is expected to result in narrower losses than previous quarters.

SINTX Announces Preliminary $2.2 Million in Q3 Revenue, Exceeding High-End Guidance

SINTX Technologies Announces Silicon Nitride Masterclass with Leading Orthopedics Experts

Experts in implant retrieval, biomaterials and clinical practice examine the science, clinical experience and potential advantages of silicon nitride relative to established implant materials in Company-sponsored Orthopedics This Week Masterclass SALT LAKE CITY, Utah, Sept. 14, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics and biomaterials company commercializing proprietary silicon nitride technologies across medical and other high-value applications, today announced the availability of a Company-sponsored Masterclass hosted by Orthopedics This Week (“OTW”), the most widely read publication in the orthopedics industry, that brings together three industry experts to present arguments examining the value of silicon nitride over legacy implant materials and to increase awareness of the impact it may have in orthopedic applications.

SINTX Technologies Announces Silicon Nitride Masterclass with Leading Orthopedics Experts

SINTX Technologies to Present at the H.C. Wainwright 28th Annual Global Investment Conference

SALT LAKE CITY, Utah, Sept. 08, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics and biomaterials company commercializing proprietary silicon nitride technologies across medical and other high-value applications, today announced that it will participate in the 28th Annual H.C.

SINTX Technologies to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Zacks Investment Research

SINTX TECHNOLOGIES (SINT) Moves to Buy: Rationale Behind the Upgrade

SINTX TECHNOLOGIES (SINT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

SINTX TECHNOLOGIES (SINT) Moves to Buy: Rationale Behind the Upgrade

SINTX Technologies Regains Compliance with Nasdaq Stockholders' Equity Requirement

SALT LAKE CITY, Utah, Aug. 13, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a company focused on advanced silicon nitride materials and medical technologies, today announced that it received written notification from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on the Nasdaq Capital Market to maintain minimum stockholders' equity of $2.5 million. Based on SINTX's Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, which reported stockholders' equity of approximately $4.83 million, Nasdaq determined that the Company complies with the minimum stockholders' equity requirement under Listing Rule 5550(b)(1) and confirmed that the previously disclosed deficiency matter is now closed.

SINTX Technologies Regains Compliance with Nasdaq Stockholders' Equity Requirement

Sintx Technologies, Inc. (SINT) Q2 2026 Earnings Call Prepared Remarks Transcript

Sintx Technologies, Inc. (SINT) Q2 2026 Earnings Call Prepared Remarks Transcript

Sintx Technologies, Inc. (SINT) Q2 2026 Earnings Call Prepared Remarks Transcript

SINTX Technologies Provides Mid-Year 2026 Business Update Highlighting Commercial Execution, Biomaterial Platform Expansion and Strategic Growth Initiatives

SALT LAKE CITY, Utah, Aug. 11, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a leader in advanced silicon nitride biomaterials and ceramics for medical and industrial applications, today provided a business update in conjunction with the filing of its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026. During the first half of 2026, SINTX advanced the commercialization of its FDA-cleared SiNAPTIC® Foot & Ankle Implant System, expanded its commercial distribution network, raised additional capital, invested in advanced manufacturing capabilities, and continued to broaden the application of its proprietary silicon nitride technology platform across multiple healthcare and industrial markets.

SINTX Technologies Provides Mid-Year 2026 Business Update Highlighting Commercial Execution, Biomaterial Platform Expansion and Strategic Growth Initiatives

SINTX Technologies Announces Second Quarter 2026 Earnings Release Date and Webcast

SALT LAKE CITY, Utah, July 28, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a leader in advanced silicon nitride ceramics and advanced material technologies, today announced that it will release its second quarter 2026 financial results on Tuesday, August 11, 2026, after the market close. The Company will also host a conference call and webcast that day at 4:30 p.m.

SINTX Technologies Announces Second Quarter 2026 Earnings Release Date and Webcast

See News Rankings

Price charts implemented using Lightweight Charts™